Baudax Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Principles (Tables)

Summary of Significant Accounting Principles (Tables)

9 Months Ended

Sep. 30, 2023

Schedule of Computation of Basic and Diluted Loss Per Share

The following table sets forth the computation of basic and diluted income (loss) per share:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
Basic and Diluted Income (Loss) Per Share
Net loss from continuing operations	$	(1,891	)	$	(4,087	)	$	(16,577	)	$	(16,626	)
Deemed dividend	$	(455	)	$	—		$	(455	)	$	—
Net loss attributable from continuing operations to common shareholders	$	(2,346	)	$	(4,087	)	$	(17,032	)	$	(16,626	)
Net income (loss) from discontinued operation	$	(43	)	$	(25,120	)	$	18,673		$	(32,920	)
Net income (loss) attributable to common shareholders	$	(2,389	)	$	(29,207	)	$	1,641		$	(49,546	)

Net loss per share from continuing operations	$	(0.29	)	$	(13.81	)	$	(3.36	)	$	(86.53	)
Net income (loss) per share from discontinued operation	$	(0.01	)	$	(84.89	)	$	3.69		$	(171.34	)
Net income (loss) per share of common stock, basic and diluted	$	(0.30	)	$	(98.70	)	$	0.33		$	(257.87	)

Weighted average common shares outstanding, basic and diluted		7,993,522			295,903			5,065,759			192,135

Schedule of Anti-Dilutive Securities

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Options and restricted stock units outstanding		977,491		606,652		977,491		606,652
Warrants		13,239,805		31,298,007		13,239,805		31,298,007
Series X Preferred Stock		20,066,208		—		20,066,208		—